진학프로석·박사 채용 접수 플랫폼

The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer researchcenter dedicated to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases. It was created in 2010, and since then has experienced exponential growth.

The IJC is also part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC) Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII).

The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six locations integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Trueta, Hospital del Mar and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.

We are looking for postdoctoral researchers in the field of biomedicine to join the Immunological Neoplasms and Precision Immunotherapy Group, led by Dr. Ari Melnick.

RESEARCH DESCRIPTION

Our lab integrates advanced animal models, spatial genomics, epigenetics, and sophisticated microscopy to dissect the biology of immune malignancies, particularly lymphomas. We emphasize translational research, bridging fundamental discoveries to clinical applications, with a goal to develop novel, targeted immunotherapies that improve patient outcomes.

Advance your career by joining a pioneering lab dedicated to unraveling immune tumor biology and translating discoveries into precision immunotherapies that can transform cancer treatment. We invite motivated and talented postdoctoral scientists to join our cutting-edge research program focused on understanding how the immune system becomes malignant, the molecular mechanisms controlling immune cancer niches, mechanisms of immune evasion, and innovative strategies to defeat these tumors using precision immunotherapies.

This position is partially supported by funding from The Leukemia & Lymphoma Society (LLS) and the Institute for Follicular Lymphoma Innovation (IFLI) through the Research Accelerator for Follicular Lymphoma (RAFL) Synergistic Team Award (SAT), under the ERADICATE Follicular Lymphoma Consortium grant."